Inflammatory signaling pathways in immune cells

Inflammatory signaling pathways in immune cells represent a diverse array of biochemical cascades that regulate the production and action of mediators involved in the host defense system (Liu et al., 2017). These pathways, including NF-κB, JAK/STAT, and MAPK, are triggered by the recognition of pathogens or endogenous danger signals via pattern recognition receptors (Newton & Dixit, 2012). Once activated, they drive the transcription of pro-inflammatory cytokines, chemokines, and adhesion molecules essential for recruiting and activating leukocytes (Taniguchi & Karin, 2018). Chronic or aberrant activation of these signaling routes is fundamentally linked to the pathogenesis of autoimmune disorders, metabolic diseases, and cancer (Furman et al., 2019). Pharmacological targeting of these pathways is a cornerstone of modern anti-inflammatory therapy, utilizing small molecules like JAK inhibitors or biologics like TNF-alpha blockers (Schett et al., 2013). While effective at reducing tissue damage, these therapies carry risks of systemic immunosuppression and increased susceptibility to opportunistic infections (Rubbert-Feld et al., 2021). Consequently, therapeutic strategies often aim for a balance between suppressing pathological inflammation and maintaining protective immunity.

Other names

Pro-inflammatory signaling cascadesImmune cell activation pathwaysCytokine-mediated signalingIntracellular inflammatory signaling

Modulation of inflammatory responses through the inhibition of specific signaling components such as kinases (e.g., JAKs), receptors (e.g., TNFR, IL-1R), or transcription factors (e.g., NF-κB) to reduce the synthesis and release of pro-inflammatory mediators (Schett et al., 2013).